Ex vivo gene transfer for improvement of transplanted pancreatic islet viability and function.
Human pancreatic islet transplantation has recently been shown to be successful in replacing pancreatic endocrine function into type 1 diabetic recipients. A major drawback, however, is the high amount of pancreatic ss cells required to render one single patient insulin-independent. Given the shortage of human beta cell donors, the majority of type 1 diabetic patients remain excluded from this therapeutic option. High number of islets are requested since substantial islet cell death and dysfunction occur within the first few hours and days after islet transplantation. Impaired vascularization of the engraft, the non-specific inflammatory reaction at the site of transplantation, together with the presence of active or memory autoimmune responses to islet autoantigens and allogeneic recognition contribute to apoptosis of ss cells and subsequent early graft function loss. This review will focus on ex vivo engineering of the islet graft by gene transfer to improve islet engraftment. An overview of currently used gene transfer techniques will be given and their potential will be discussed.
Van Linthout
S
S
Experimental Medicine and Gene Therapy, INBB, Viale Sant'Antonio SNC, 07033 Osilo, Italy. svlint@yahoo.co.uk
Madeddu
P
P
D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy; D015316:Genetic Therapy; D005822:Genetic Vectors; D006085:Graft Survival; D006801:Humans; D007515:Islets of Langerhans / Q000502:physiology*; D016381:Islets of Langerhans Transplantation / Q000379:methods*